LabNetwork Integrates with Reaxys to Offer Seamless Experience from Chemistry Research to Purchase

Monday, March 27, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LabNetwork collaboration simplifies and accelerates purchasing decisions for chemical companies and researchers

SHANGHAI and BOSTON, March 26, 2017 /PRNewswire/ -- LabNetwork, WuXi AppTec's global chemistry ecommerce platform company, today announced a new collaboration

with Elsevier, a world-leading provider of scientific, technical and medical information products and services.

LabNetwork's nearly four million commercially available discovery and research compounds will now be directly available to users of Reaxys, Elsevier's premier chemistry database. The enhanced functionality means chemical companies and researchers, while using Reaxys, will also have access to both LabNetwork product availability and price information as a standard feature. The implementation deepens WuXi's integration with chemists' research and discovery workflows and expands exposure to WuXi ecommerce through LabNetwork.

Through the integration chemical companies and researchers can now enjoy product quality assurance that is guaranteed by WuXi, greater transparency over supply chains, and lower costs for a range of vital compounds on Reaxys. Researchers will also reap the advantages of a wider selection as LabNetwork sources compounds from more than 2,000 suppliers across the globe. Finally, the integration means that researchers will be able to easily compare the cost of buying a compound versus making it internally, allowing them to save time, accelerate research and better allocate budget resources.

"We are always looking for ways to support our customers to become more efficient and successful in their research," commented Dr. Thibault Géoui, Senior Director for Chemistry Solutions at Elsevier. "This integration with LabNetwork streamlines a process that thousands of researchers undertake many times a day. Speeding up these activities helps companies' commercialize their own compounds faster, meaning that customers in rapidly developing markets, such as China, will benefit in particular. Not only because they will have peace of mind about the quality of the product they are investing in, but by boosting exports as well as improving in-country R&D."

Dr. Xuanjia Peng, Head of LabNetwork, commented, "We're excited to work with Elsevier, a world leading research tool in the chemistry and life science industries, to better serve the global research community with more cost effective research chemicals to lower research cost. LabNetwork is committed to provide researchers across the world with unprecedented access to LabNetwork's commercially available compounds from a broad range of quality sources."

About WuXi AppTecWuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit

About LabNetworkLabNetwork, a wholly owned subsidiary of WuXi AppTec, is a global eCommerce platform with the vision of connecting suppliers and buyers of research products. Backed by WuXi AppTec's expertise in R&D, sourcing, quality control, warehousing and logistics, LabNetwork brings trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide. Our mission is to enable scientists anywhere in the world to leverage the LabNetwork platform to conduct their research more efficiently and cost effectively. For more information, please visit:

About ElsevierElsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

About ReaxysReaxys contains over 240 years of unparalleled chemistry content, including: 105 million organic, inorganic and organometallic compounds, 41 million chemical reactions, 500 million published experimental facts, 16,000 chemistry related periodicals, and six indexing sources for a cross-disciplinary view of chemistry.

To view the original version on PR Newswire, visit:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store